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Abstract: Although the lignan compound fargesin is a major ingredient in Shin-Yi, the roles of
fargesin in carcinogenesis and cancer cell growth have not been elucidated. In this study, we
observed that fargesin inhibited cell proliferation and transformation by suppression of epidermal
growth factor (EGF)-stimulated G1/S-phase cell cycle transition in premalignant JB6 Cl41 and HaCaT
cells. Unexpectedly, we found that signaling pathway analyses showed different regulation patterns
in which fargesin inhibited phosphatidylinositol 3-kinase/AKT signaling without an alteration of
or increase in mitogen activated protein kinase (MAPK) in JB6 Cl41 and HaCaT cells, while both
signaling pathways were abrogated by fargesin treatment in colon cancer cells. We further found that
fargesin-induced colony growth inhibition of colon cancer cells was mediated by suppression of the
cyclin dependent kinase 2 (CDK2)/cyclin E signaling axis by upregulation of p21WAF1/Cip1, resulting
in G1-phase cell cycle accumulation in a dose-dependent manner. Simultaneously, the suppression of
CDK2/cyclin E and induction of p21WAF1/Cip1 were correlated with Rb phosphorylation and c-Myc
suppression. Taken together, we conclude that fargesin-mediated c-Myc suppression inhibits EGF-
induced cell transformation and colon cancer cell colony growth by the suppression of retinoblastoma
(Rb)-E2F and CDK/cyclin signaling pathways, which are mainly regulated by MAPK and PKB
signaling pathways.
Keywords: fargesin; cell proliferation; carcinogenesis; chemoprevention; therapeutic compound
1. Introduction
Oriental medicinal herbs and dietary foods contain many useful bioactive ingredi-
ents and have been considered as a natural storage containing novel compounds that
may have therapeutic value against human diseases. Some of these compounds such as
myricetin, quercetin, epigallocatechin gallate, and flavonoids in dietary foods and tea con-
tain chemopreventive effects such as inhibition of cell proliferation and transformation [1]
by inhibition of the extracellular signal-regulated kinases (ERKs)/p90 ribosomal S6 kinases
(RSKs) signaling pathway in a non-toxic manner [2]. For the last decade, our laboratory has
paid attention to the ingredients of Shin-Yi, the dried flower buds of Magnolia fargesii Cheng
(Magnoliaceae), which has been used in the treatment of emphysema, nasal congestion,
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sinusitis, and allergic rhinitis [3]. Tetrahydrofurofuranoid lignans including magnolin,
aschantin, epimagnolin, dimethoxyaschantin, dimethylliroresinol, dimethylpinoresinol,
and fargesin are major and pharmacologically active ingredients of Shin-Yi [3–10]. Pre-
viously, our research demonstrated that magnolin targeted the active pockets of ERK1
and ERK2 by forming hydrogen bonds with Lys168 of ERK1 and Met108 and Lys54 of
ERK2, resulting in a 68 nM IC50 for ERK1 and a 16.5 nM IC50 for ERK2 [11]. Moreover, our
research interest was expanded to include identifying the molecular targets of aschantin
and epimagnolin [12–14]. The results demonstrated that those two compounds targeted
the active pocket of the mTOR kinase with a less than 400 nM IC50 [11–13]. However, other
Shin-Yi compounds that might have biological activities in diverse human diseases have
not been elucidated.
A recent study revealed that fargesin increases basal glucose uptake by induction
of phosphorylation of AKT at Ser473 but does not affect AMPK phosphorylation [15].
Interestingly, transactivation activities of the transcription factors nuclear factor-kappa
B (NF-kB) and activator protein-1 (AP-1), which are well-known transcription factors
that regulate multiple pro-inflammatory genes and carcinogenesis, were suppressed by
fargesin in a protein kinase C (PKC)-dependent manner [16]. Although the effects of
fargesin on anti-inflammatory and antioxidant properties have been elucidated, the role
and anticancer effects of fargesin have not been reported. Since mTOR has essential
roles in cell proliferation, cell transformation, protein synthesis, and the nutritional level
sensory response [17], mTOR allosteric inhibitors that suppress mTORC1 activity have
been considered to be able to potentiate in cancer growth suppression. However, the
phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR signaling pathway plays a key role in
cancer cell proliferation by regulating cell cycle modulation [18], and the inhibition may
be toxic to normal cells. Since natural compounds originating from medicinal herbs have
generally been found to have low toxicity [19], identification of non-toxic compounds from
medicinal herbs that can target the mTOR kinase is important.
The c-Jun protein is a central component of the mammalian transcription factor AP-1
complex and it has a key role in the regulation of diverse cellular processes including cell
proliferation, transformation, and cancer development [20]. Since the AP-1 transcription
factor regulates about 60% of tumorigenesis-related gene expression in eukaryotic cells,
the signaling pathways that regulate AP-1 transactivation activity are of special interest in
cancer therapy. Importantly, phosphorylation of the c-Jun C-terminus at Ser243 by glycogen
synthase kinase 3 β (GSK3β) is reported to lead to Fbxw7 binding and degradation of
c-Jun [21]. Previously, we demonstrated that aschantin targeting of the active pocket of
the mTOR kinase suppresses epidermal growth factor (EGF)-induced phosphorylation of
AKT at Ser473, resulting in a reduction in the total c-Jun protein level via ubiquitination-
dependent destabilization [12]. The reduction in total c-Jun protein levels by aschantin
treatment resulted in inhibition of c-Jun/AP-1 transactivation activity and suppression
of cell growth in MIAPaCa-2 pancreas and LNCaP prostate cancers [12]. Thus, signaling
pathways that regulate c-Jun/AP-1 transactivation activity and protein stability have
been considered to have importance as chemopreventive and therapeutic agents of cancer.
However, the effects of fargesin on cancer cell growth have not yet been elucidated.
2. Results
2.1. Fargesin-Mediated G1/S Cell Cycle Transition Inhibition Suppresses EGF-Induced Cell
Proliferation and Transformation
Fargesin is a lignan compound and a major ingredient of Shin-Yi, along with magnolin,
aschantin, and epimagnolin (Supplemental Figure S1). Although recent research has indi-
cated that fargesin has an important role in the inhibition of inflammatory responses and
glucose metabolism, the roles of fargesin in cell proliferation and cell transformation in car-
cinogenesis have not been fully elucidated. Since JB6 Cl41 mouse skin epidermal cells and
HaCaT human skin keratinocytes have been widely used to analyze the potency of chemo-
prevention and therapeutic compounds in tumor promoter-induced carcinogenesis [20],
both were used to initially examine the inhibitory effects of fargesin on cell proliferation.
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We observed that fargesin suppressed cell proliferation of JB6 Cl41 and HaCaT cells in
a dose-dependent manner (Figure 1a). Both JB6 Cl41 and HaCaT cells showed a 50%
inhibitory effect of cell proliferation at approximately 22–23 µM fargesin concentration
(Figure 1a). Next, we explored the effect of fargesin on cell cycle phase distribution in
normal cell culture conditions. We found that fargesin treatment induced the G1-phase
cell cycle population in JB6 Cl41 and HaCaT cells in a dose-dependent manner (Figure 1b).
In contrast, the S-phase cell cycle population was suppressed by fargesin treatment in both
JB6 Cl41 and HaCaT cells in a dose-dependent manner (Figure 1b). Additionally, we did not
observe the cytotoxic effects of fargesin at 60 µM by 48 h in JB6 Cl41 cells (Supplemental Fig-
ure S2) as well as fargesin-induced apoptosis in JB6 Cl41 and HaCaT cells by 48 h and 72 h,
respectively (Supplemental Figure S3). The cell cycle distribution of JB6 Cl41 and HaCaT
cells in normal cell culture conditions was similar to the previous literature [11,13,22]. To
examine whether the G1-phase cell cycle accumulation of JB6 Cl41 and HaCaT cells treated
by fargesin was mediated by a growth factor-induced G1/S cell cycle transition or not, we
starved the cells and co-treated them with EGF and fargesin as indicated. We observed
that EGF stimulation increased the S-phase cell cycle population and reduced the G1-phase
cell cycle population in JB6 Cl41 and HaCaT cells (Figure 1c). Notably, the EGF-induced
S-phase increase was abolished by fargesin treatment in JB6 Cl41 and HaCaT cells in a dose-
dependent manner (Figure 1c). In contrast to the S phase, the decreased G1-phase cell cycle
population by EGF stimulation was increased by fargesin treatment in JB6 Cl41 and HaCaT
cells (Figure 1c). Oscillation of cell cycle phases of the G1 and S phases was shown to be
in accordance with fargesin’s dose dependence (Figure 1c). Since anchorage-independent
colony growth is a hallmark of cell transformation from normal cells to cancer cells [20],
we further examined the inhibitory activity of fargesin on anchorage-independent cell
transformation induced by tumor promoters, such as EGF [11,20]. As expected, we found
that JB6 Cl41 and HaCaT cell colony formation in soft agar was significantly induced by
EGF (Figure 1d). We also observed that fargesin suppressed the EGF-induced anchorage-
independent colony formation in a dose-dependent manner (Figure 1d). These inhibitory
effects of fargesin were similarly observed in both JB6 Cl41 and HaCaT cells. Taken together,
these results demonstrate that fargesin contains anti-proliferative and anti-carcinogenic
potentials by suppression of the tumor promoter-induced G1/S-phase cell cycle transition
at the promotion stage.
2.2. Effects of Fargesin on the Cell Proliferation and Colony Growth of Colon Cancer Cells
Previously, we demonstrated that magnolin and aschantin, which are major ingredi-
ents harboring a similar chemical structure to fargesin and abundantly present in Shin-Yi,
suppressed the colony growth of lung and prostate cancer cells by targeting the active pock-
ets of ERK1/2 and the mTOR kinase, respectively [11,12]. Moreover, we found that fargesin
suppressed cell proliferation and EGF-induced cell transformation (Figure 1). These results
suggest that fargesin might have inhibitory effects on cancer cell proliferation and colony
growth. Based on this rationale, we examined the effects of fargesin on the cell proliferation
and colony growth of colon cancer cells including HCT116, WiDr, and HCT8 cells. We
found that fargesin inhibited cell proliferation of these cells in a dose-dependent manner
(Figure 2a). However, despite the dose dependency, HCT116, WiDr, and HCT8 showed
different sensitivities for fargesin-mediated IC50 values for cell proliferation inhibition,
about 35, 38, and 45 µM, respectively (Figure 2a). Notably, fargesin treatment increased
the G1/G0-phase cell cycle population and decreased the S-phase cell cycle population
in these colon cancer cells (Figure 2b), as similarly shown in premalignant cells such as
JB6 Cl41 and HaCaT cells (Figure 1b,c). Since cancer cells already escape from cell-to-cell
contact inhibition, we explored fargesin’s effects on the foci formation ability of cancer cells.
We found that fargesin inhibited foci formation of colon cancer cells in a dose-dependent
manner (Figure 2c, and Supplemental Figure S4A). The IC50 of fargesin in foci formation
was about 30 µM in HCT116 and WiDr, whereas the IC50 value in HCT8 cells was about 40
µM (Figure 2c). Next, we examined the effects of fargesin on the anchorage-independent
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colony growth of colon cancer cells. As expected, fargesin suppressed the colony growth of
colon cancer cells in a dose-dependent manner (Figure 2d, and Supplemental Figure S4B).
Interestingly, WiDr colon cancer cells showed stronger sensitivity for fargesin compared
to HCT116 and HCT8 cells. The effects of fargesin on colon cancer cell proliferation and
colony growth suggested to us that fargesin contains not only a chemopreventive, but also
a therapeutic potential for tumor promoter-induced cell transformation and colon cancer










Figure 1. Fargesin-mediated G1/S cell cycle transition inhibition suppresses EGF-induced cell pro-
liferation and transformation. (a) Inhibitory effects of fargesin on cell proliferation of JB6 Cl41 and 
HaCaT cells. JB6 Cl41 (1 × 103 cells) and HaCaT (0.65 × 103 cells) were seeded into 96-well cell cul-
ture plates, cultured overnight, and treated with indicated doses of fargesin. Cell proliferation was 
measured at indicated times by MTS assay as described in “Material and Methods”. (b) The effects 
of fargesin on the cell cycle phase distribution of JB6 Cl41 and HaCaT cells. JB6 Cl41 (5 × 105 cells) 
and HaCaT (2.5 × 105 cells) were seeded into 60-mm cell culture dishes, cultured overnight, and 
treated with indicated doses of fargesin for 24 h. The cell cycle phase population was measured by 
flow cytometry. (c) The effects of fargesin on cell cycle transition induced by EGF stimulation in 
JB6 Cl41 and HaCaT cells. JB6 Cl41 (5 × 105 cells) and HaCaT (2.5 × 105 cells) were seeded into 60-
mm cell culture dishes, cultured overnight, starved for 24 h by feeding 0.1% FBS, and treated with 
indicated doses of EGF and fargesin for 24 h. The cell cycle phase population was measured by 
flow cytometry. (d) The effects of fargesin on the EGF-induced cell transformation in JB6 Cl41 and 
HaCaT cells. JB6 Cl41 (8 × 103 cells) and HaCaT (8 × 103 cells) were mixed with 0.32% top agar sup-
plemented with indicated doses of EGF and fargesin and poured onto bottom agar, which con-
tained indicated doses of EGF and fargesin. After the top agar hardened, the cells were cultured 
for 10–14 days at 37 °C, in a 5% CO2 incubator. The colonies were observed under an ECLIPSE Ti 
inverted microscope and scored using the NIS-Elements AR (V. 4.0) computer program. (a–d) 
Data: a triplicate experiment; values: ± SEM; significance: * p < 0.05, ** p < 0.01 vs. non-treated con-
trol by Student’s t-test. 
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Figure 1. Fargesin-mediated G1/S cell cycle transition inhibition suppresses EGF-induced cell
proliferation and transformation. (a) Inhibitory effects of fargesin on cell proliferation of JB6 Cl41
and HaCaT cells. JB6 Cl41 (1 × 103 cells) and HaCaT (0.65 × 103 cells) were seeded into 96-well cell
c lture plates, c ltured overnight, and treated with indicated doses of fargesin. Cell proliferati s
t indicated times by MTS as ay as described in “Material and Methods”. (b) The eff cts of
fargesin o the c ll cycle phase distribution f JB6 Cl41 and HaCaT cells. JB6 Cl41 (5 × 105 cells) and
HaCaT (2.5 × 105 cells) were seeded into 60-mm cell culture dishes, cultured overnight, and treated
with indicated doses of fargesin for 24 h. The cell cycle phase population was measured by flow
cytometry. (c) The effects of fargesin on cell cycle transition induced by EGF stimulation in JB6 Cl41
and HaCaT cells. JB6 Cl41 (5 × 105 cells) and HaCaT (2.5 × 105 cells) were seeded into 60-mm cell
culture dishes, cultured overnight, starved for 24 h by feeding 0.1% FBS, and treated with indicated
doses of EGF and fargesin for 24 h. The cell cycle phase population was measured by flow cytometry.
(d) The effects of fargesin on th EGF-induced cell transformation in JB6 Cl41 and HaCaT cells. JB6
C 41 (8 × 103 cells) and HaCaT (8 × 103 cells) were mixed with 0.32% top agar supplemented with
indicated doses of EGF and fargesin and poured onto b ttom agar, which contained indi ated doses
of EGF and fargesin. After the top agar hardened, the cells ere cultured for 10–14 days at 37 ◦C,
in a 5% CO2 incubator. The colonies were observed under an ECLIPSE Ti inverted microscope and
scored using the NIS-Elements AR (V. 4.0) computer program. (a–d) Data: a triplicate experiment;
values: ±SEM; significance: * p < 0.05, ** p < 0.01 vs. non-treated control by Student’s t-test.
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Figure 2. Effects of fargesin on the cell proliferation and colony growth of colon cancer cells. (a) 
Fargesin inhibits cell proliferation of colon cancer cells. HCT116 (2 × 103), WiDr (1 × 103), and 
HCT8 (1 × 103) colon cancer cells were seeded into 96-well plates, cultured overnight, and treated 
with indicated doses of fargesin. Cell proliferation inhibition was measured by MTS assay with 24-
Figure 2. Effects of fargesin on the cell proliferation and colony growth of colon cancer cells. (a) Far-
gesin inhibits cell proliferation of colon cancer cells. HCT116 (2 × 103), WiDr (1 × 103), and HCT8
(1 × 103) colon cancer cells were seeded into 96-well plates, cultured overnight, and treated with
indicated d ses of fargesin. Cell proliferation inhibition was measured by MTS assay with 24-h
intervals up to 96 h. (b) Fargesin induces the G1 phase of and suppresses the S phase of the cell
cycle population in colon cancer cells. HCT116 (2 × 105), WiDr (2 × 105), and HCT8 (2 × 105)
colon cancer cells were seeded into 60-mm cell culture dishes, cultured overnight, and treated with
fargesin (60 µM) for 24 h. The cell cycle phase population was measured by flow cytometry. (c) The
effects of fargesin on the foci formation of colon cancer cells. HCT8 (1 × 103), WiDr (1 × 103), and
HCT116 (1 × 103) cells were seeded into 6-well cell culture plates, cultured overnight, and treated
with indicated doses of fargesin. The cells were cultured for 7–10 days and foci formation was
visualized by crystal violet staining/destaining. (d) The effects of fargesin on the colony growth
of colon cancer cells. HCT116 (8 × 103), WiDr (8 × 103), and HCT8 (8 × 103) colon cancer cells
were mixed with 0.32% top agar supplemented with indicated doses of fargesin and poured onto
bottom agar, which contained indicated doses of fargesin. After the top agar hardened, the cells
were cultured for 10–14 days at 37 ◦C, in a 5% CO2 incubator. The colonies were observed under an
ECLIPSE Ti inverted microscope and scored using the NIS-Elements AR (V. 4.0) computer program.
(a–d) Data: a triplicate experiment; values: ±SEM; significance: * p < 0.05, ** p < 0.01 vs. non-treated
control by Student’s t-test.
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2.3. Fargesin Induced Morphological Changes by Suppression of PI3K/PKB Signaling Pathway
Previous studies indicated that fargesin did not alter the morphological change in
cells in vitro and in vivo [23,24]. However, we observed that fargesin induced a significant
morphological change in JB6 Cl41 and HCT8 colon cancer cells (Figure 3a). The cells
became longish and emaciated in JB6 Cl41 cells (Figure 3a, left panels) and flattened and
enlarged in HCT8 colon cancer cells (Figure 3a, right panels). Since fargesin attenuated cell
proliferation (Figure 2), we hypothesized that the morphological change might be involved
in cell proliferation and colony growth. To address this question, we firstly examined the
phosphoprotein profiles of signaling molecules, focusing on the ERKs and the PI3K/AKT
signaling pathways in JB6 Cl41 cells. We found that phosphorylation of mitogen-activated
protein kinase kinase (MEK), an upstream kinase of ERK1/2, was induced by the EGF
treatment but was not altered by fargesin treatment (Figure 3b). Interestingly, the unex-
pected results repeatedly show that EGF-induced ERKs’ and RSKs’ phosphorylation was
increased by fargesin treatment in a dose-dependent manner (Figure 3b). In addition, total
protein levels of MEKs, ERKs, and RSKs were not changed by EGF alone or EGF/fargesin
combined treatment (Figure 3b). By analyzing the PKB signaling pathway, EGF-induced
mTOR phosphorylation at Ser2448 and AKT phosphorylation at Thr308 and Ser473 were
observed (Figure 3c), as shown in our previous reports [11,12]. In contrast to ERKs and
RSKs, phosphorylation of mTOR at Ser2448 and AKT at Thr308 and Ser473 was decreased
by fargesin treatment in a dose-dependent manner (Figure 3c). However, we did not know
the reason why AKT phosphorylation at Thr308 by co-treatment of EGF and 15 µM of
fargesin was increased (Figure 3c). These results suggest that fargesin might target a sig-
naling molecule in the PI3K/protein kinase B (PKB) pathway. To examine whether cancer
cells also showed similar phosphorylation patterns for ERKs and PI3K/PKB signaling
pathways, or not, we conducted Western blot analysis. We found that fargesin suppressed
phosphorylation levels of MEKs, ERKs, and RSKs in WiDr and HCT8 colon cancer cells
(Figure 3d). Similarly, phosphorylation levels of PI3K/PKB signaling molecules were
inhibited by fargesin treatment in WiDr and HCT8 colon cancer cells (Figure 3e). These
results indicate that fargesin-mediated inhibition of ERKs and PKB signaling pathways
suppresses colon cancer cell proliferation and colony growth.
2.4. Modulation of CDKs/Cyclins-p21WAF1/Cip1 Signaling Axis by Fargesin Induces G1/G0 Cell
Cycle Accumulation
Our previous results demonstrated that fargesin inhibited the cell proliferation and
colony growth of colon cancer cells by induction of G1/G0 cell cycle accumulation (Figure 2).
The cell proliferation and colony growth inhibitions might be mediated via inhibition of
the growth factor-mediated ERKs and PI3K/PKB signaling pathways in colon cancer cells
(Figure 3). We further found that fargesin dramatically induced the G1/G0-phase cell cycle
population and reduced the S-phase cell cycle population compared to non-treated control
cells (Figure 2b). These results indicated that the fargesin-mediated cell proliferation and
colony growth inhibitions in colon cancer cells were associated with impairment of the
G1/S cell cycle progression. ERKs and PKB signaling pathway-mediated CDKs and cyclins
generally regulate cell proliferation and survival by the mediation of gene expression and
protein synthesis [2,11,12,18]; however, it is not clear whether cell cycle control by fargesin
is mediated by the cell cycle regulators such as CDK2/4 and cyclin D/E. Based on this
rationale, we analyzed the protein levels of CDK2/4 and cyclin D1/E in colon cancer cells.
We observed that CDK4 was reduced in HCT8 and HCT116, but not in WiDr, by fargesin
treatment (Figure 4a). Moreover, cyclin D1 was downregulated in WiDr and HCT116, but not
in HCT8, by fargesin treatment (Figure 4a). The results suggest that the CDK4 and cyclin D1
signaling pathway may partially involve fargesin-mediated cell cycle regulation. In contrast,
CDK2 and cyclin E protein levels were dramatically decreased in WiDr, HCT8, and HCT116
colon cancer cells by fargesin treatment in a dose-dependent manner (Figure 4a). Since
p21WAF1/Cip1 is a well-known regulator for CDK2/cyclin E signaling-mediated cell cycle
regulation, we examined whether fargesin-mediated G0/G1 accumulation of the cell cycle
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phase and CDKs/cyclins downregulation are related to p21WAF1/Cip1 protein levels or not.
We found that fargesin induced p21WAF1/Cip1 protein levels in WiDr, HCT8, and HCT116
colon cancer cells in a dose-dependent manner (Figure 4b). Similarly, we also found that
fargesin induced p21WAF1/Cip1 protein levels in JB6 Cl41 cells in a dose-dependent manner
(Figure 4c). These results were supported by our immunocytofluorescence assays indicating
that p21WAF1/Cip1 protein levels were highly detected in the cytoplasm as well as the nucleus
with fargesin treatment in WiDr and HCT8 colon cancer cells in a dose-dependent manner
(Figure 4d). Taken together, these results suggest that fargesin induced complex formation
of p21WAF1/Cip1/CDK2/cyclin E, resulting in impairment of the G1/S cell cycle transition
and inhibition of cell proliferation of premalignant JB6 Cl41 and HaCaT cells, as well as












Figure 3. Fargesin induced morphological changes by suppression of PI3K/PKB signaling path-
way. (a) Fargesin induces morphology changes in cells. JB6 Cl41 (5 × 104) and HCT8 (5 × 104) cells 
were seeded into 6-well plates, cultured overnight, and treated with indicated doses of fargesin. 
Representative photographs were obtained by observation under a light microscope (×200). (b–e) 
Effects of fargesin on the phosphorylation of ERKs and PI3K/AKT signaling pathways. Phospho-
protein profiles of MEKs/ERKs/RSKs signaling pathway (b and d) and PI3K/AKT signaling path-
way (c,e) in JB6 Cl41 (b,c) and WiDr and HCT8 colon cancer cells (d,e). Total proteins (20 µg) ex-
tracted from JB6 Cl41 and colon cancer cells were resolved by SDS-PAGE and transferred onto 
PVDF membrane. The indicated proteins were visualized by probing the specific antibodies. β-
actin was used to verify equal protein loadings. 
2.4. Modulation of CDKs/Cyclins-p21WAF1/Cip1 Signaling Axis by Fargesin Induces G1/G0 Cell 
Cycle Accumulation 
Our previous results demonstrated that fargesin inhibited the cell proliferation and 
colony growth of colon cancer cells by induction of G1/G0 cell cycle accumulation (Figure 
2). The cell proliferation and colony growth inhibitions might be mediated via inhibition 
of the growth factor-mediated ERKs and PI3K/PKB signaling pathways in colon cancer 
cells (Figure 3). We further found that fargesin dramatically induced the G1/G0-phase cell 
cycle population and reduced the S-phase cell cycle population compared to non-treated 
control cells (Figure 2b). These results indicated that the fargesin-mediated cell prolifera-
tion and colony growth inhibitions in colon cancer cells were associated with impairment 
of the G1/S cell cycle progression. ERKs and PKB signaling pathway-mediated CDKs and 
Figure 3. Fargesin induced morphological changes by suppression of PI3K/PKB signaling pathway.
(a) Fargesin induces morphology changes in cells. JB6 Cl41 (5 × 104) and HCT8 (5 × 104) cells were
seeded into 6-well plates, cultured overnight, and treated with indicated doses of fargesin. Representative
photographs were bt ined by observation under a light microscope (×200). (b–e) Effects of fargesin
on he phosphoryla ion of ERKs and PI3K/A T signaling pathways. Phosp oprotein profiles of
MEKs/ERKs/RSKs signaling pathway (b,d) and PI3K/AKT signaling pathway (c,e) in JB6 Cl41 (b,c) and
WiDr and HCT8 colon cancer cells (d,e). Total proteins (20 µg) extracted from JB6 Cl41 and colon cancer
cells were resolved by SDS-PAGE and transferred onto PVDF membrane. The indicated proteins were
visualized by probing the specific antibodies. β-actin was used to verify equal protein loadings.
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cyclins generally regulate cell proliferation and survival by the mediation of gene expres-
sion and protein synthesis [2,11,12,18]; however, it is not clear whether cell cycle control 
by fargesin is mediated by the cell cycle regulators such as CDK2/4 and cyclin D/E. Based 
on this rationale, we analyzed the protein levels of CDK2/4 and cyclin D1/E in colon cancer 
cells. We observed that CDK4 was reduced in HCT8 and HCT116, but not in WiDr, by 
fargesin treatment (Figure 4a). Moreover, cyclin D1 was downregulated in WiDr and 
HCT116, but not in HCT8, by fargesin treatment (Figure 4a). The results suggest that the 
CDK4 and cyclin D1 signaling pathway may partially involve fargesin-mediated cell cycle 
regulation. In contrast, CDK2 and cyclin E protein levels were dramatically decreased in 
WiDr, HCT8, and HCT116 colon cancer cells by fargesin treatment in a dose-dependent 
manner (Figure 4a). Since p21WAF1/Cip1 is a well-known regulator for CDK2/cyclin E signal-
ing-mediated cell cycle regulation, we examined whether fargesin-mediated G0/G1 accu-
mulation of the cell cycle phase and CDKs/cyclins downregulation are related to 
p21WAF1/Cip1 protein levels or not. We found that fargesin induced p21WAF1/Cip1 protein levels 
in WiDr, HCT8, and HCT116 colon cancer cells in a dose-dependent manner (Figure 4b). 
Similarly, we also found that fargesin induced p21WAF1/Cip1 protein levels in JB6 Cl41 cells 
in a dose-dependent manner (Figure 4c). These results were supported by our immuno-
cytofluorescence assays indicating that p21WAF1/Cip1 protein levels were highly detected in 
the cytoplasm as well as the nucleus with fargesin treatment in WiDr and HCT8 colon 
cancer cells in a dose-dependent manner (Figure 4d). Taken together, these results suggest 
that fargesin induced complex formation of p21WAF1/Cip1/CDK2/cyclin E, resulting in im-
pairment of the G1/S cell cycle transition and inhibition of cell proliferation of premalig-










Figure 4. Modulation of CDKs/cyclins-p21WAF1/Cip1 signaling axis by fargesin induces G0/G1 cell 
cycle accumulation. (a) Fargesin suppresses protein levels of cell cycle regulators involved in G1/S 
cell cycle transition. Total proteins (30 μg) extracted from the indicated cells were separated by 
SDS-PAGE, and the indicated proteins were visualized by probing the specific antibodies indi-
cated. β-actin was used to verify equal protein loadings. (b–c) Fargesin induces p21WAF1/Cip1 protein 
levels in colon cancer cells. Total proteins (30 μg) extracted from WiDr, HCT8, and HCT116 colon 
cancer cells (b) and JB6 Cl41 cells (c) were resolved by SDS-PAGE and visualized by probing the 
p21WAF1/Cip1 antibody and the HRP-conjugated secondary antibody. β-actin was used to verify 
equal protein loadings. (d) Fargesin induces a p21WAF1/Cip1-positive cell population. WiDr (1 × 104 
cells) and HCT8 (1 × 104 cells) colon cancer cells were seeded into 4-chamber slides, cultured for 48 
h, and treated with indicated doses of fargesin. The cells were fixed with 4% paraformaldehyde, 
Figure 4. Modulation of CDKs/cyclins-p21WAF1/Cip1 signaling axis by fargesin induces G0/G1 cell
cycle accumulation. (a) Fargesin suppresses protein levels of cell cycle regulators involved in G1/S
cell cycle transition. Total proteins (30 µg) extracted from the indicated cells were separated by
SDS-PAGE, and the indicated proteins were visualized by probing the spe ific antibodies indicated.
β-actin was used to verify equal protein l i . (b, r si induces p21WAF1/Cip1 protein
levels in colo cancer cells. Total proteins (30 µg) extracted from WiDr, HCT8, and HCT116 colon
cancer cells (b) and JB6 Cl41 cells (c) were resolved by SDS-PAGE and visualized by probing the
p21WAF1/Cip1 antibody and the HRP-conjugated secondary antibody. β-actin was used to verify equal
protein loadings. (d) Fargesin induces a p21WAF1/Cip1-positive cell population. WiDr (1 × 104 cells)
and HCT8 (1 × 104 cells) colon cancer cells were seeded into 4-chamber slides, cultured for 48 h,
and treated with indicated doses of fargesin. The cells were fixed with 4% paraformaldehyde,
permeabilized, and hybridized with a p21WAF1/Cip1 specific antibody and Alexa 568-conjugated
secondary antibody. The cells were observed under a fluorescence confocal microscope (×200).
Representative photographs were obtained from a photograph taken randomly at four different
locations/chamber in three independent experiments. Red, p21WAF1/Cip1; blue, nuclear.
2.5. Differential Regulation of AP-1 Signaling and C-Myc-Mediated CDK2/Cyclin E Signaling
Mediates Cell Proliferation Differentially in Premalignant and Cancer Cells
Growth factor-stimulated cell cycle progression for the G1/S transition plays a key
role in normal controlled cell proliferation and abnormal cancerous cell transformation.
Based on the previous literature, transactivation activities of AP-1, a dimer of Fos and
Jun, and c-Myc play a pivotal role in G1/S cell cycle transition. Since our research group
has published that tumor promoters such as EGF or TPA induce AP-1 transactivation
activity-mediated cell proliferation and transformation in JB6 Cl41 cells, we identified
c-Fos and c-Jun protein levels to be important targets for signaling molecules during
EGF-induced cell proliferation and transformation. Moreover, a large body of studies has
also shown that c-Myc can modulate the expression of genes controlling the cell cycle,
especially the G1-phase CDKs, and primarily CDK2, and thereby facilitate transit through
the G1/S transition [25]. Thus, we analyzed c-Jun and c-Fos protein levels in JB6 Cl41
cells. We found that EGF stimulation induced c-Jun and c-Fos levels in JB6 Cl41 cells
(Figure 5a). Notably, JB6 Cl41 cells showed a decrease in c-Jun and c-Fos protein levels by
fargesin treatment in a dose-dependent manner, whereas HaCaT cells showed a decrease
in only c-Fos, but not in c-Jun, protein levels by fargesin in a dose-dependent manner
(Figure 5a). Notably, by the AP-1 luciferase reporter assay, we confirmed that fargesin
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also suppressed AP-1 transactivation activity in these cells in a dose-dependent manner
(Figure 5b). Interestingly, protein level changes of c-Jun and c-Fos were not observed after
fargesin treatment of HCT8 and WiDr colon cancer cells in normal cell culture conditions
(Figure 5c) as well as EGF-stimulated conditions (Figure 5d). Meanwhile, c-Myc protein
levels were dramatically reduced by fargesin treatment in HCT8 and WiDr colon cancer
cells in a dose-dependent manner (Figure 5e). Notably, phosphorylated retinoblastoma
(Rb) protein levels were inhibited by fargesin treatment in a dose-dependent manner,
while total levels of the Rb protein in steady state were maintained (Figure 5f). Since the
Myc promoter contains an E2F binding site [26] and fargesin suppresses G1/S cell cycle
transition in colon cancer cells, we examined the c-Myc protein levels at the nucleus and
cytosol by immunocytofluorescence (Supplemental Figure S5). The results indicate that
the c-Myc protein mainly observed in the nucleus in the non-treated control group had a
weak intensity (Figure 5g, left panels, and Supplemental Figure S5) and showed diffusion
into the cytosol (Figure 5g, bottom panels, and Supplemental Figure S5). The normalized
intensity of green fluorescence showed that c-Myc protein levels were dramatically reduced
by fargesin treatment (Figure 5g, graphs). Taken together, our results demonstrate that
fargesin suppressed EGF-induced cell proliferation and cell transformation in premalignant
cells and cell proliferation and colony growth of colon cancer cells by modulation of cell
cycle regulators via CDK2/cyclin E/p21WAF1/Cip1 complex formation. Thus, fargesin can
















Figure 5. Differential regulation of AP-1 signaling and c-Myc-mediated CDK2/cyclin E signaling 
mediates cell proliferation differentially in premalignant and cancer cells. (a) Fargesin suppresses 
EGF-induced c-Jun and c-Fos protein levels in JB6 Cl41 and HaCaT cells. Cell lysates (30 μg) ex-
tracted from JB6 Cl41 and HaCaT cells were utilized to examine the protein levels of c-Jun and c-
Fos by Western blotting using specific antibodies as indicated. (b) Fargesin inhibits AP-1 transacti-
vation activity. JB6 Cl41 (5 × 104) cells stably transfected with AP-1 luciferase reporter plasmid 
were subjected to AP-1 transactivation activity analysis as described in “Materials and Methods”. 
Data: a triplicate experiment; values: ± SEM; significance: * p < 0.05, ** p < 0.01 vs. non-fargesin-
treated control by Student’s t-test. (c–d) Fargesin did not alter c-Jun and c-Fos protein levels in 
both normal and EGF-stimulated cell culture conditions in colon cancer cells. Cell lysates (30 μg) 
extracted from WiDr and HCT8 cells (c) and EGF-stimulated WiDr and HCT8 cells (d) were uti-
lized to examine the protein levels of c-Jun and c-Fos by Western blotting using specific antibodies 
as indicated. (e) Fargesin suppresses c-Myc protein levels in colon cancer cells. Cell lysates (30 μg) 
extracted from WiDr and HCT8 cells were subjected to analyze c-Myc protein levels by Western 
blotting using the c-Myc specific antibody as indicated. (f) Fargesin suppresses phosphorylation of 
Rb protein. Cell lysates (30 μg) extracted from WiDr and HCT8 cells were subjected to analysis of 
phosphorylation levels of Rb protein levels by Western blotting using the phospho- and total-spe-
cific Rb antibodies as indicated. (g) Fargesin suppresses c-Myc protein levels in both the cytosol 
and nucleus. Right panels: WiDr (2 × 104) cells were seeded into four-chamber slides, cultured 
overnight, and treated with the indicated doses of fargesin for 6 h. The cells were fixed, permea-
bilized, and hybridized with c-Myc-specific primary antibody and Alexa 488-conjugated second-
ary antibody. The c-Myc was observed under confocal microscope (×200). The original images 
with c-Myc (Alexa 488 shown as green) and DAPI (shown as blue) and the merged images are in 
Supplementary Figure S5. Graphs: The fluorescence intensity was measured by the Image J com-
puter program and normalized with DAPI intensity. Representative photographs were obtained 
from a photograph taken randomly at four different locations/chamber in three independent ex-
periments. DAPI indicates nuclei. Data: a triplicate experiment; values: ± SEM; significance: ** p < 
0.01 vs. non-fargesin-treated control by Student’s t-test. (a–f) β-actin was used to verify equal pro-
tein loadings. 
Figure 5. Differential regulation of AP-1 signaling and c-Myc-mediated CDK2/cyclin E signaling
mediates cell proliferation differentially (a) Fargesin suppresses EGF-induced c-Jun and c-Fos protein
levels in JB6 Cl41 and HaCaT cells. Cell lysates (30 µg) extracted from JB6 Cl41 and HaCaT cells were
utilized to examine the protein l vels of c-Jun an c-Fos by West rn blotting using specific antibodies
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as indicated. (b) Fargesin inhibits AP-1 transactivation activity. JB6 Cl41 (5 × 104) cells stably
transfected with AP-1 luciferase reporter plasmid were subjected to AP-1 transactivation activity
analysis as described in “Materials and Methods”. Data: a triplicate experiment; values: ±SEM;
significance: * p < 0.05, ** p < 0.01 vs. non-fargesin-treated control by Student’s t-test. (c,d) Fargesin
did not alter c-Jun and c-Fos protein levels in both normal and EGF-stimulated cell culture conditions
in colon cancer cells. Cell lysates (30 µg) extracted from WiDr and HCT8 cells (c) and EGF-stimulated
WiDr and HCT8 cells (d) were utilized to examine the protein levels of c-Jun and c-Fos by Western
blotting using specific antibodies as indicated. (e) Fargesin suppresses c-Myc protein levels in colon
cancer cells. Cell lysates (30 µg) extracted from WiDr and HCT8 cells were subjected to analyze
c-Myc protein levels by Western blotting using the c-Myc specific antibody as indicated. (f) Fargesin
suppresses phosphorylation of Rb protein. Cell lysates (30 µg) extracted from WiDr and HCT8
cells were subjected to analysis of phosphorylation levels of Rb protein levels by Western blotting
using the phospho- and total-specific Rb antibodies as indicated. (g) Fargesin suppresses c-Myc
protein levels in both the cytosol and nucleus. Right panels: WiDr (2 × 104) cells were seeded
into four-chamber slides, cultured overnight, and treated with the indicated doses of fargesin for 6
h. The cells were fixed, permeabilized, and hybridized with c-Myc-specific primary antibody and
Alexa 488-conjugated secondary antibody. The c-Myc was observed under confocal microscope
(×200). The original images with c-Myc (Alexa 488 shown as green) and DAPI (shown as blue)
and the merged images are in Supplementary Figure S5. Graphs: The fluorescence intensity was
measured by the Image J computer program and normalized with DAPI intensity. Representative
photographs were obtained from a photograph taken randomly at four different locations/chamber
in three independent experiments. DAPI indicates nuclei. Data: a triplicate experiment; values:
±SEM; significance: ** p < 0.01 vs. non-fargesin-treated control by Student’s t-test. (a–f) β-actin was
used to verify equal protein loadings.
3. Discussion
Within its major ingredients, Shin-Yi extract contains eight different lignan compounds
including eudesmin, magnolin, lirioresinol, epimagnolin, aschantin, kubusin, fargesin,
and burchellin, which have very similar chemical structures. Shin-Yi has been used as an
oriental medicine, generally in order to treat inflammation-mediated diseases including
nasal congestion associated with headache, sinusitis, and allergic rhinitis [27]. Although
the effects of a medicinal cocktail that includes Shin-Yi are well-known, it is unclear which
chemical compounds produce the medicinal effects. Moreover, the molecular targets
and action mechanisms have not been clearly described. Our laboratory has undertaken
studies to identify the molecular targets of some active natural compounds originating
from oriental medicinal herbs, which have revealed the molecular action mechanisms
through combinational approaches of molecular biology and biochemistry along with
computational and structural prediction analysis. Previously, we reported that magnolin
targets the active pocket of ERK1 and ERK2 with about 68 and 16.5 nM in IC50 values,
respectively [11]. The molecular biology and biochemical analyses demonstrated that
magnolin competed with ATP at the active pocket of ERK2 [11], whereas the computational
and structural prediction analyses suggested that magnolin formed hydrogen bonds with
Lys 168 of ERK1 and Met168 and Lys54 of ERK2 [11]. Moreover, aschantin, a major
ingredient of Shin-Yi with a similar chemical structure to that of magnolin, targets the
active pocket of the mTOR kinase [12]. Aschantin was shown to form a hydrogen bond
with Val2240 of the mTOR kinase domain [12]. Interestingly, magnolin did not alter
the phosphoprotein profiles of MAPK signaling molecules [12]. Moreover, aschantin
did not inhibit protein kinase activities of PI3K, PDK-1, or AKT [11,12]. Recently, our
research group reported that epimagnolin, a stereochemical epimer of magnolin, targets
the active pocket of the mTOR kinase, but not that of ERK1 and ERK2, contrasting with
our expectation that epimagnolin could inhibit the activity of ERK1 and ERK2 [13]. These
results demonstrated that slight differences in chemical structure might produce large
differences in the molecular targeting of proteins that are involved in human diseases
including cancers. Although molecular targeting of fargesin was not conducted in this
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study, signaling studies using fargesin have demonstrated that fargesin stimulates glucose
uptake and consumption by GLUT4 translocation to the cytoplasmic membrane [15].
Moreover, fargesin inhibits pro-inflammatory modulators such as cyclooxygenase-2 and
inducible nitric oxide synthase, resulting in suppression of inflammatory responses in
THP-1 monocytes. Notably, production of interleukin-1β and tumor necrosis factor-β,
pro-inflammation cytokines, and CCL-5, a chemokine, was inhibited by fargesin [16].
Importantly, transactivation activities of the transcription factors nuclear factor-kappa
B (NF-kB) and activator protein-1 (AP-1), which are well-known transcription factors
that regulate multiple pro-inflammatory genes and carcinogenesis, were suppressed by
fargesin in a protein kinase C (PKC)-dependent manner [16]. Our results demonstrate that
fargesin suppressed AP-1 transactivation activity (Figure 5a,b), resulting in EGF-induced
cell transformation (Figure 1d). Since fargesin suppressed AKT phosphorylation at Thr308
and Ser473, we suggest that the target molecule(s) of fargesin may be an AKT upstream,
including receptor tyrosine kinases at the cytoplasmic membrane.
The c-fos and c-jun proto-oncogenes, components of the AP-1 transcription factor, are
essential transcription factors involved in cell transformation and tumorigenesis [28,29].
CDK2, a serine/threonine kinase, has a role in the G1/S-phase cell cycle progression, DNA
synthesis initiation, and the exit regulation from the S phase. In the G1/S-phase transition
process, the CDK4/6-cyclin D complex initially phosphorylates the Rb protein [30,31].
After this event, CDK2 and cyclin E associate and the CDK2/cyclin E complex phospho-
rylates Rb [32], resulting in the release of E2F transcription factors to prepare for gene
expression in the G1/S-phase cell cycle transition and in DNA synthesis [23]. Thus, since
the CDK2/cyclin E complex is maximal in the G1 cell cycle phase, CDK2 and cyclin E
protein levels are critically important in the prediction of cell cycle progression. In the
present study, our results show that fargesin treatment reduced total protein levels of
CDK2 and cyclin E (Figure 4a), which are critical components of the G1/S-phase cell cycle
transition [18]. Other recent results have indicated that Jun D knockdown can reduce the
protein levels of cell cycle regulators including c-Myc, CDK4, and CDK2 in prostate cancer
cells [24]. In contrast, the protein levels of c-Myc, CDK4, and CDK2 were increased by over-
expression of Jun D in prostate cancer cells [24]. These results suggest that AP-1-mediated
c-Myc and CDKs have key roles in the G1/S-phase cell cycle transition. Surprisingly, in this
study, we observed that fargesin treatment reduced the protein levels of c-Fos and c-Jun
(Figure 5a), resulting in the suppression of AP-1 transactivation activity (Figure 5b), which
was measured by firefly luciferase activity using cell lysates from stable cells harboring
the AP-1 luciferase report plasmid in the genome [14]. Notably, the total protein levels of
c-Myc and CDK2 were reduced by fargesin treatment in colon cancer cells (Figure 5e,g and
Figure 4a). These results demonstrate that fargesin-mediated cell cycle modulation inhibits
cell proliferation via AP-1-mediated gene expression of cell cycle regulators such as c-Myc
and CDK2.
Interestingly, we found that fargesin treatment did not reduce the phosphorylation
levels of signaling molecules in MAPK. In contrast to our hypothesis, fargesin increased
the phosphorylation levels of ERK1/2 and RSKs (Figure 3b). Furthermore, a previous
publication indicated that fargesin induces AKT phosphorylation, and wortmannin, a
PI3K inhibitor, showed conversely suppressed fargesin-induced AKT phosphorylation [14].
However, we showed that fargesin inhibited EGF-induced phosphorylation levels of mTOR
and AKT in JB6 Cl41 premalignant (Figure 3c) and WiDr and HCT8 colon cancer cells
(Figure 3e). Importantly, we further found that fargesin increased the total protein level of
p21WAF1/Cip1 (Figure 4b,c), but not of p16INK4a (data not shown), suggesting that fargesin
target signaling is via a CDK2/cyclin E rather than a CDK4/cyclin D signaling cascade
(Figure 4a). This suggestion is supported by recent results finding that c-Myc induces
cyclin E and suppresses p21WAF1/Cip1 [24], resulting in the induction of cell proliferation.
Moreover, gene expression aberration of CDK2 and cyclin E affects the G1/S-phase cell
cycle progression [18]. Our results demonstrate that fargesin inhibits cell proliferation via
suppression of the G1/S-phase cell cycle transition (Figure 1b,c and Figure 2b), resulting in
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abrogation of EGF-induced cell transformation. We also observed G1-phase cell accumula-
tion following fargesin treatment in HCT8, WiDr, and HCT116 colon cancer cells. Notably,
fargesin suppressed the colony growth of colon cancer cells in an anchorage-independent
condition. Unfortunately, the involvement of p53 phosphorylation at Ser37 as an upstream
transcription factor of p21WAF1/Cip1 has not been clearly elucidated. Taken together, the
results of this study strongly indicate that fargesin has potential as a chemoprevention
and/or therapeutic agent against human cancer.
4. Materials and Methods
4.1. Chemicals and Antibodies
Chemicals utilized for the molecular and cellular biology investigations and for buffer
preparation were purchased from Sigma-Aldrich (St. Louis, MO, USA). Cell culture
media including RPMI 1640, modified Eagle’s medium, and Dulbecco’s modified Eagle’s
medium were purchased from Corning (Corning, New York, NY, USA). Fetal bovine
serum (FBS) and supplements including penicillin and streptomycin were purchased
from Life Science Technologies (Rockville, MD, USA) and were heat inactivated before
utilization. Dimethyl sulfoxide (DMSO, Sigma-Aldrich) was purchased from Sigma-Aldrich
(St. Louis, MO, USA). Recombinant EGF was purchased from ThermoFisher Scientific
Korea (Gangnam, Seoul, Korea). Antibodies for phosphoproteins and total proteins in the
MAPK signaling pathway including MEKs, ERK1/2, and RSKs were purchased from Cell
Signaling Technology (Beverly, MA, USA). Antibodies for PKB signaling and cell cycle
regulation pathways including phospho-AKT (S473), phospho-AKT (T308), total-CDK4,
and total-cyclin D1 were purchased from Cell Signaling Technology (Beverly, MA, USA)
to use in Western blot analyses. Phospho- and total-antibodies for transcription factors
including phospho-c-Jun (S63), phospho-c-Jun (S73), and total-c-Jun were purchased from
Cell Signaling Technology (Beverly, MA, USA). Antibodies including c-Myc, p21WAF1/Cip1,
p16INK4a, CDK2, cyclin E, and β-actin were from Santa Cruz Biotechnology (Santa Cruz,
CA, USA).
4.2. Fargesin
Fargesin, with a >99.0% product purity confirmed by performing high-performance
liquid chromatography, was generously provided by Dr. SR Oh of the Korean Research
Institute of Bioscience and Biotechnology (Korea patent # 10-0321212-0000) [5] as described
previously. The fargesin stock solution (100 mM: 1000×) was prepared by dissolving it in
DMSO, after which aliquots were prepared and then stored at −20 ◦C. Fargesin working
solutions were freshly diluted in DMSO before utilization. When fargesin was treated
into cells, cells were treated upon medium exchange with a premixed fargesin cell culture
medium. The DMSO concentration did not exceed 0.1% of the total final volume.
4.3. Cell Culture
All cells including premalignant JB6 Cl41 and HaCaT cells and HCT8, WiDr, and
HCT116 colon cancer cells were obtained from the American Type Culture Collection
(Manassas, VA, USA). The JB6 Cl41 cells were cultured in MEM supplemented with final
5% FBS. The HCT116 and HaCaT cells were cultured in DMEM supplemented with final
10% FBS. The colon cancer cells, including HCT8 and WiDr, were cultured in RPMI-1640
supplemented with final 10% FBS. Cell lines were periodically authenticated by monitoring
cell morphology, by growth curve analysis, and by undertaking mycoplasma contamination
inspection. When cells reached 90% confluence, the cells were split for passage prior to
seeding for experiments. Fresh complete medium was refed every other day.
4.4. Cell Proliferation Assay
To measure cell proliferation, JB6 Cl41 cells (1 × 103), HaCaT cells (0.65 × 103),
HCT8 cells (1 × 103), WiDr cells (1 × 103), or HCT116 cells (2 × 103) were seeded
into 96-well plates (100 µL of cell culture medium) and cultured overnight, and ab-
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sorbance was measured (0 h) at 492 nm followed by the 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-based CellTiter 96®
Aqueous One Solution assay according to the manufacturer’s suggested protocols (Promega,
Madison, WI, USA). Briefly, 20 µL of the MTS solution was added to each well and incu-
bated for 1 h at 37 ◦C in a 5% CO2 incubator, and then the reaction was stopped by adding
25 µL of 10% sodium dodecyl sulfate (SDS) solution to each well. The absorbance was
measured immediately at 492 nm using an xMark microplate spectrophotometer (Bio-Rad
Laboratories, Hercules, CA, USA). The effects of fargesin on cell proliferation were eval-
uated by comparing the absorbance of the samples to a DMSO-treated control group at
24-h intervals.
4.5. Cytotoxicity Assay
JB6 Cl41 cells (1× 104) were seeded into 96-well plates and cultured overnight, and cell
viability was measured at 0 h by an MTS assay as described in “Cell Proliferation Assay”.
The cells were treated with fargesin by exchanging medium containing the indicated
doses of fargesin. The cell viability was measured at 24 and 48 h. The absorbance was
measured immediately at 492 nm using an xMark microplate spectrophotometer (Bio-Rad
Laboratories). The effects of fargesin on cell viability were evaluated by comparing the
absorbance of the samples to a DMSO-treated control group.
4.6. Cell Cycle Analysis
JB6 Cl41 cells (5 × 105), HaCaT cells (2.5 × 105), HCT8 cells (2 × 105), WiDr cells
(2 × 105), or HCT116 (2× 105) cells were seeded into 60-mm dishes and cultured overnight.
To analyze the effect of fargesin on the cell cycle distribution under normal cell culture
conditions, JB6 Cl41 and HaCaT cells were treated with fargesin in complete cell culture
medium for 24 h. The effect of fargesin on the cell cycle phase transition by EGF was exam-
ined by exchange of starvation medium (MEM supplemented with 0.1% FBS) overnight
following treatment of EGF or co-treatment of EGF and indicated doses of fargesin for 24 h.
The cells were trypsinized, fixed, treated with RNase A (100 µg/mL), and then incubated
at room temperature for 1 h. The population in each cell cycle phase was measured by
propidium iodide (20 µg/mL) staining and flow cytometry followed flow cytometry (BD
FACSCalibur™ flow cytometer, Franklin Lakes, NJ, USA).
4.7. Western Blotting
Cell lysates were extracted by freezing and thawing in cell lysis buffer (50 mM Tris
pH 8.0, 150 mM NaCl, 1% NP-40, Roche protease inhibitor cocktail). Equal amounts of
protein (generally 20–30 µg/lane) were resolved by SDS-PAGE, transferred onto polyvinyli-
dene difluoride (PVDF, Merck Millipore Ltd., Burlington, MA, USA) membranes, blocked
in a blocking buffer (5% skim milk/1× PBS), and then hybridized with specific antibodies.
Blots were washed three times in 1× TBS-T buffer and rehybridized with the appropriate
HRP-conjugated secondary antibodies. The proteins were visualized with an enhanced
chemiluminescence detection system (Amersham Biosciences, Piscataway, NJ, USA).
4.8. Luciferase Assay
For the AP-1 luciferase assay, JB6 Cl41 cells (5 × 104 cells) stably transfected with
AP-1 luciferase reporter plasmids were cultured in 24-well plates. The cells were treated
with the indicated doses of fargesin for 12 h. The firefly luciferase activity was measured
by luminescence detection system (VICTOR X3 plate reader, PerkinElmer, Waltham, MA,
USA) using equal volumes of the cell lysates.
4.9. Anchorage-Independent Cell Transformation Assay
JB6 Cl41 and HaCaT cells were utilized to evaluate the inhibitory effects of fargesin
on EGF-induced cell transformation. The cells (8 × 103 cells/well/6-well plates) were
exposed to EGF alone (10 ng/mL) or equal concentrations of EGF and the indicated doses
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of fargesin in 1 mL of 0.3% top agar composed of basal medium Eagle agar containing
10% FBS. The cultures were continuously cultured for 10–14 days. The cell colonies were
observed under an ECLIPSE Ti inverted microscope and scored using the NIS-Elements AR
(V. 4.0) computer software program (NIKON Instruments Korea, Gangnam, Seoul, Korea).
4.10. Colony Growth Assay of Cancer Cells (Soft Agar Assay)
The inhibitory effects on cancer colony growth by fargesin treatment were assessed
using HCT8, WiDr, and HCT116 colon cancer cells. Briefly, colon cancer cells (8 × 103)
suspended in appropriate complete culture medium supplemented with 10% FBS were
added to 0.3% top agar containing the indicated doses of fargesin into 6-well plates. The
cultures were continuously cultured for 10–14 days. The cell colonies were observed
under an ECLIPSE Ti inverted microscope and scored using the NIS-Elements AR (V. 4.0)
computer software program (NIKON Instruments Korea).
4.11. Focus Formation Assay
HCT8 cells (1 × 103), WiDr cells (1 × 103), or HCT116 cells (1 × 103) were seeded
into 6-well plates and cultured overnight. The cells were continuously maintained with
complete medium supplemented with the indicated doses of fargesin for 7–10 days. The
cells were subjected to Crystal Violet staining (0.05% w/v Crystal Violet, 1% formaldehyde,
1× PBS, 1% methanol) and destained. The formed foci were scanned by using an EPSON
scanner and were scored by using Image J software.
4.12. Immunocytofluorescence Assay
HCT8 cells (4 × 104) were seeded into four-chamber culture slides and cultured for
24 h. Subsequently, the cells were starved for 18 h, pretreated with the indicated doses
of fargesin for 30 min, and co-treated with EGF and fargesin for 30 min as indicted. The
cells were fixed, permeabilized, and hybridized with the specific antibody overnight at
4 ◦C in a humidified chamber. The proteins were visualized by using secondary antibody
hybridization conjugated with Alexa 488 or 568 under an LSM 710 laser scanning confocal
microscope (Carl Zeiss, Oberkochen, Germany).
5. Conclusions
The physiological and preventive roles of fargesin in colon cancer cells were clearly
shown by cancer cell proliferation and colony growth assays. Moreover, fargesin-mediated
inhibition of colon cancer cell proliferation and colony growth is positively co-related
to G1/S cell cycle transition inhibition. The molecular mechanism studies suggest that
CDK2/cyclin E and CDK4/cyclin D are involved in the inhibition of colon cancer cell
proliferation by fargesin via p21WAF1/Cip1 and c-Myc, respectively.
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